

# Curriculum Vitae Assoc.-Prof. Dr. Tanja N. Hartmann

## Personal details

Name: Tanja Nicole Hartmann  
Date of Birth: 26.03.1974  
Nationality: German  
Marital status: married  
Name of Birth: Huber  
Address (work): Internal Medicine I and Comprehensive Cancer Center Freiburg,  
University Clinics Freiburg,  
Hugstetter Straße 49, 79106 Freiburg, Germany.  
Phone: +49-761-270-71511  
Fax: +49-761-270-33980  
Email: tanja.hartmann@uniklinik-freiburg.de  
Address (private): Dorfstraße 13, 79194 Heuweiler, Germany.

## Research focus

Malignant and normal cell homing, microenvironment, cytoskeleton, integrins, leukemia.

## Education

05/2015 Venia docendi (Habilitation) in molecular biology at the Paris Lodron University of Salzburg: "Integration of adhesive and migratory cues in leukemic cells".  
03/2015 Master course "Health Sciences and Leadership" at the Paracelsus Medical University Salzburg. Level 1 grade (basic level, 2 semesters, 42 ECTS).  
07/2013 Venia docendi (Habilitation) in tumor biology at the Paracelsus Medical University Salzburg: "The interplay of adhesion molecules and chemokine receptors in tumor cell- microenvironment interactions".  
06/2002 Ph.D.; University of Freiburg, Germany, Thesis: "Regulation of glutathione biosynthesis in poplars".  
05/1999 Degree: Diploma in Biology; University of Freiburg, Germany.  
1993 Abitur, Klosterschule vom Heiligen Grab Baden-Baden, Germany.

## Employment and Positions

07/2018 onwards Scientific group leader Internal Medicine I, University Clinics Freiburg, Germany.  
07/2018 onwards Scientific coordinator Comprehensive Cancer Center Freiburg, Germany.  
07/2018 onwards Expert advisor and external group leader "*CLL Trafficking*" at the Salzburg Cancer Research Institute- Laboratory for Immunological and Molecular Cancer Research and the Cancer Cluster Salzburg.  
03/2017 onwards Associate Professor for Tumor Biology of the Paracelsus Medical University, Salzburg, Austria.  
01/2009-07/2018 Deputy Head of the Laboratory for Immunological and Molecular Cancer Research, Third Medical Department (Head Prof. Richard Greil), Paracelsus Medical University, Salzburg, Austria.  
03/2008-07/2018 Group leader "*CLL Trafficking*" at the Laboratory for Immunological and Molecular Cancer Research Third Medical Department, Paracelsus Medical University, Salzburg, Austria.  
02/2006-02/2008 Minerva postdoctoral fellow, Weizmann Institute of Science, Rehovot, Israel, Department of Immunology, group of Prof. Ronen Alon, "*Investigation of chemokine-integrin signaling at endothelial and extravascular contacts*".  
07/2002 - 02/2006 Postdoctoral fellow, Freiburg University Hospital, Germany, Department of Internal Medicine, group of Meike and Jan Burger, Project: "*Investigation of the function of chemokine receptors in tumor progression and chemoresistance*".  
07/1999 - 06/2002 Ph. D student, University of Freiburg, Germany; Institute of Tree Physiology, Faculty of Forestry, Degree: Ph. D. in Biological Sciences, Supervision of Heinz Rennenberg, Thesis: "*Regulation of glutathione biosynthesis in poplars*".

## *Curriculum Vitae Assoc.-Prof. Dr. Tanja N. Hartmann*

### **Grants (peer reviewed third-part funding)**

- 03/2018-02/2021 FWF Grant W1213 doctoral program project part leader *“Tumor cell-microenvironment interactions in leukemia”*.
- 01/2018-12/2018 Research Fund from the Paracelsus Medical University (PMU-FFF # E-17/25/130-HAH), for the project *“Defining the contribution of VLA-4 to leukemic retention and proliferation in lymphoid organs – therapeutic implications”*.
- 06/2016-06/2017 Research Fund from the Paracelsus Medical University (PMU-FFF # E-15/22/114-HAR), for the project *“CD44 cooperation with VLA-4 in acute myeloid leukemia”*, completed.
- 10/2015-09/2018 FWF Grant W1213 doctoral program project part leader *“Integration of microenvironmental signals in functional responses of chronic lymphocytic leukemia (CLL) cells”*.
- 07/2014-06/2015 Research Fund from the Paracelsus Medical University (PMU-FFF #E-13/18/093-HAR), for the project *“How does trisomy 12 switch CLL homing to the bone marrow from a CXCR4-dependent to a CXCR4-independent process”*, completed.
- 01/2014-06/2018 FWF Grant P26421-B13 for the project *“The role of the integrin-linked kinase in normal and malignant B lymphocytes”*.
- 10/2013-09/2015 Research Fund from the Monika Kutzner Stiftung for the collaborative project *“Die Rolle des atypischen Chemokin-Rezeptors CRAM in der Chronisch Lymphatischen Leukämie“* by Tanja Hartmann and Meike Burger, Freiburg, Germany (equal contributions), completed.
- 11/2012-04/2014 Research Fund from the Paracelsus Medical University (PMU-FFF #E-12/15/074-HAH), for the project *“Alterations in chemokine and beta1 integrin induced Rac signaling in chronic lymphocytic leukaemia”*, completed.
- 08/2012-08/2016 FWF Grant P25015-B13 for the project *“The role of CD44-hyaluronan interactions in the pathophysiology of chronic lymphocytic leukemia”*, completed.
- 10/2010-08/2012 Research Fund from the Paracelsus Medical University (PMU-FFF #E-10/11/058-HAR), for the project *“The role of integrin-linked kinase in B-cell chronic lymphocytic leukaemia”*, completed.
- 07/2009-07/2012 Grant (“Jubiläumsfond”) of the Österreichische Nationalbank (OeNB) for the project OeNB13420 *“The role of the VLA-4 integrin in adhesion and survival of chronic lymphocytic leukemia cells”*, completed.
- 02/2006-02/2008 Minerva (Max Planck) postdoctoral fellowship in the Weizmann Institute of Science, Israel, for the project *“The role of VLA-4 and LFA-1 in the adhesion, locomotion and transendothelial migration of non-malignant and malignant B cells”*, completed.

### **Awards**

- June 2010 *“Researcher of the year 2009”*, Paracelsus Private Medical University Salzburg.

### **Teaching activities**

- Lecturer *“Tumor and Stem Cell Biology”* and *“Tumor Immunology”*, University Salzburg, Faculty of Molecular Biology, (2011-2018).
- Lecturer *“Molecular Medicine”*, Paracelsus Medical University Salzburg (2010-2018).
- Lecturer *“Tumor Immunology”* for medical students of the Paracelsus Medical University Salzburg (2008-2018).
- Annual guest lecturer *“Tumorbiology”*, FH Furtwangen, Germany (2013-2016).
- Design and supervision of experimental student course, part *“Methods of Molecular Biology”*, Institute of Molecular Medicine, University of Freiburg (2005).
- Annual biochemical seminars (9 hours per year) for undergraduate students at the Faculty of Forestry of the University of Freiburg (1998-2001).

### **Network organization**

- Co-founder and Deputy Head of the Cancer Cluster Salzburg (founded 2013).

## *Curriculum Vitae Assoc.-Prof. Dr. Tanja N. Hartmann*

### **Congress organization**

Scientific organization of the 5<sup>th</sup> to 13<sup>th</sup> Annual International CLL Workshop "Update on Biology and Therapy of Chronic Lymphocytic Leukemia" in Hof (Lake Fuschl), Salzburg, Austria (2009-2018).

Scientific organization of the 1st to 3rd International Meeting of the Cancer Cluster Salzburg in Hof (Lake Fuschl), Salzburg, Austria (2015-2018).

Member of the Organizing Committee of the 3<sup>rd</sup> and 7<sup>th</sup> ÖGMBT Annual Meeting 2011 and 2015, Salzburg, Austria.

### **Committee work**

Member of the Habilitation Committee of the Paracelsus Medical University Salzburg, Austria (since December 2013).

Member of the Committee for Biosafety of the Paracelsus Medical University Salzburg, Austria (since July 2015).

Member of the Curriculum Committee for the new Biology Master Degree "Medical Biology", Paris-Lodron University Salzburg (2015/2016), Austria.

Member of the Review Board of the Research Support Funds of the Paracelsus Medical University, Salzburg, Austria (since March 2017).

### **Reviewing activity**

#### Peer Reviewer for the Journals:

JCI, PNAS, Blood, Leukemia, Haematologica, FEBS Letters, Expert Opinion on Biological Therapy, Blood Cancer Journal, Journal of Hematological Malignancies, BMC Cancer, International Journal of Cancer.

#### Peer Reviewer for the Funding Bodies:

Leukemia and Lymphoma Society (Site Visiting Expert and Grant Reviews), North West Cancer Research Fund, NHS GGC.

#### Member of Abstract Reviewer Committee for Conferences:

Annual Meeting of the American Society of Hematology (ASH 2013), Annual Meeting DGHO/ÖGHO/SGMO/SGH 2013.

**10 most important publications**

Gutjahr JC, Szenes E, Tschach L, Asslaber D, Schlederer M, Roos S, Yu X, Girbl T, Sternberg C, Egle A, Aberger F, Alon R, Kenner L, Greil R, Orian-Rousseau V, **Hartmann TN**, 2018. Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia. *Blood* 131(12):1337-49.

Tissino E, Benedetti D, Herman SEM, ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, **Hartmann TN\***, Gattei V\*, and Zucchetto A\*, 2018. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. *J Exp Med* 215(2):681-97.

\* equal contribution.

Krenn PW, Hofbauer SW, Pucher S, Hutterer E, Hinterseer E, Denk U, Asslaber D, Ganghammer S, Sternberg C, Neureiter D, Aberger F, Wickström SA, Egle A, Greil R, **Hartmann TN**, 2016. ILK induction in lymphoid organs by a TNF $\alpha$ -NF- $\kappa$ B-regulated pathway promotes the development of chronic lymphocytic leukemia. *Cancer Res* 76(8):2186-96.

Hofbauer SW, Krenn PW, Ganghammer S, Asslaber D, Pichler U, Oberascher K, Henschler R, Wallner M, Kerschbaum H, Greil R, **Hartmann TN**, 2014. Tiam1/Rac1 signals contribute to proliferation and chemoresistance but not motility of chronic lymphocytic leukemia cells. *Blood* 123(14):2181-8.

Girbl T, Hinterseer E, Grössinger EM, Asslaber D, Oberascher K, Weiss L, Hauser-Kronberger C, Neureiter D, Kerschbaum H, Naor D, Alon R, Greil R, **Hartmann TN**, 2013. CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21 induced motility *Cancer Res* 73(2):561-70.

**Hartmann TN**, Grabovsky V, Wang W, Desch P, Rubenzer G, Wollner S, Binsky I, Vallon-Eberhard A, Sapoznikov A, Haran M, Shachar I, Burger M, Honczarenko M, Greil R, Alon R, 2009. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. *Cancer Res* 69(7): 3121-3130.

**Hartmann TN**, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A, Nagler A, Lapidot T, Thelen M, Alon R, 2008. A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine triggered motility of human T lymphocytes and CD34+ cells. *J Leukoc Biol* 84(4):1130-40.

Woolf E, Grigorova I, Sagiv A, Grabovsky V, Feigelson SW, Shulman Z, **Hartmann T**, Sixt M, Cyster JG, Alon R, 2007. Lymph node chemokines promote sustained T lymphocyte motility without triggering stable integrin adhesiveness in the absence of shear forces. *Nat Immunol* 8: 176-85.

**Hartmann TN**, Burger JA, Glodek A, Fujii N, Burger M, 2005. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. *Oncogene* 24(27):4462-71.

Burger M, **Hartmann T**, Rawluk J, Fujii N, Kipps TJ, Burger JA, 2005. Small Peptide Inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration and antiapoptotic responses of CXCL12 in Chronic Lymphocytic Leukemia B cells. *Blood* 106(5):1824-30.